Literature DB >> 35557567

Prognostic nomogram for predicting cancer-specific survival in patients with resected hilar cholangiocarcinoma: a large cohort study.

Zhimin Yu1,2, Qinghua Liu1,2, Hao Liao1,2, Juanyi Shi1,2, Zhenyu Zhou1,2, Yongcong Yan1,2, Junyao Xu1,2, Chuanchao He1,2, Kai Mao1,2, Jianlong Zhang1,2, Jie Wang1,2, Zhiyu Xiao1,2.   

Abstract

Background: The aim of the study was to establish and validate a novel prognostic nomogram of cancer-specific survival (CSS) in resected hilar cholangiocarcinoma (HCCA) patients.
Methods: A training cohort of 536 patients and an internal validation cohort of 270 patients were included in this study. The demographic and clinicopathological variables were extracted from the Surveillance, Epidemiology and End Results (SEER) database. Univariate and multivariate Cox regression analysis were performed in the training cohort, followed by the construction of nomogram for CSS. The performance of the nomogram was assessed by concordance index (C-index) and calibration plots and compared with the American Joint Committee on Cancer (AJCC) staging systems. Decision curve analysis (DCA) was applied to measure the predictive power and clinical value of the nomogram.
Results: The nomogram incorporating age, tumor size, tumor grade, lymph node ratio (LNR) and T stage parameters was with a C-index of 0.655 in the training cohort, 0.626 in the validation cohort, compared with corresponding 0.631, 0.626 for the AJCC 8th staging system. The calibration curves exhibited excellent agreement between CSS probabilities predicted by nomogram and actual observation in the training cohort and validation cohort. DCA indicated that this nomogram generated substantial clinical value. Conclusions: The proposed nomogram provided a more accurate prognostic prediction of CSS for individual patients with resected HCCA than the AJCC 8th staging system, which might be served as an effective tool to stratify resected HCCA patients with high risk and facilitate optimizing therapeutic benefit. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Hilar cholangiocarcinoma (HCCA); SEER; cancer-specific survival (CSS); nomogram; surgery

Year:  2022        PMID: 35557567      PMCID: PMC9086037          DOI: 10.21037/jgo-21-543

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  49 in total

1.  Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma?

Authors:  Abdul R Hakeem; Gabriele Marangoni; Stephen J Chapman; Richard S Young; Amit Nair; Ernest L Hidalgo; Giles J Toogood; Judy I Wyatt; Peter A Lodge; K R Prasad
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-09       Impact factor: 2.566

2.  Suggestions for improving perihilar cholangiocarcinoma staging based on an evaluation of the seventh edition AJCC system.

Authors:  Wooil Kwon; Jin-Young Jang; Ye Rim Chang; Woohyun Jung; Mee Joo Kang; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2015-01-09       Impact factor: 3.452

3.  Actual long-term outcome of extrahepatic bile duct cancer after surgical resection.

Authors:  Jin-Young Jang; Sun-Whe Kim; Do Joong Park; Young Joon Ahn; Yoo-Seok Yoon; Min Gew Choi; Kyung-Suk Suh; Kuhn Uk Lee; Yong-Hyun Park
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

Review 4.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

5.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

6.  Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme.

Authors:  Fabio Bagante; Thuy Tran; Gaya Spolverato; Andrea Ruzzenente; Stefan Buttner; Cecilia G Ethun; Bas Groot Koerkamp; Simone Conci; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Gerardo Vitiello; Jan N M IJzermans; Shishir K Maithel; George Poultsides; Alfredo Guglielmi; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2016-02-26       Impact factor: 6.113

7.  Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma.

Authors:  Hai-Jie Hu; Rong-Xing Zhou; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jiong Lu; Jun-Ke Wang; Yong Zhou; Fu-Yu Li
Journal:  Oncotarget       Date:  2017-10-23

8.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.

Authors:  Shahid A Khan; Brian R Davidson; Robert D Goldin; Nigel Heaton; John Karani; Stephen P Pereira; William M C Rosenberg; Paul Tait; Simon D Taylor-Robinson; Andrew V Thillainayagam; Howard C Thomas; Harpreet Wasan
Journal:  Gut       Date:  2012-08-15       Impact factor: 23.059

9.  Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.

Authors:  Peizhan Chen; Bin Li; Yan Zhu; Wei Chen; Xin Liu; Mian Li; Xiaohua Duan; Bin Yi; Jinghan Wang; Chen Liu; Xiangji Luo; Xiaoguang Li; Jingquan Li; Lijian Liang; Xiaoyu Yin; Hui Wang; Xiaoqing Jiang
Journal:  Oncotarget       Date:  2016-06-14

10.  Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma.

Authors:  Yaodong Zhang; Zhengshan Wu; Xing Wang; Changxian Li; Jiang Chang; Wangjie Jiang; Hongwei Wang; Yirui Wang; Xiangcheng Li
Journal:  BMC Cancer       Date:  2020-10-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.